$CMPS has been mentioned by 2 distinct FinTwit voices over a 12-month period from November 2025 through April 2026, with 5 total mentions. @adamfeuerstein discussed the stock 3 times, while @investmentguru_ contributed 2 mentions. The biotech category dominated discussion of this ticker. First mention occurred on 2025-11-04, with the most recent discussion on 2026-04-20.

Conversations centered on Compass Pathways' psilocybin drug COMP360 and its clinical trial results for treatment-resistant depression. @adamfeuerstein noted that results from two trials support FDA approval prospects but raised questions about competitive positioning. @investmentguru_ included $CMPS in a broader watchlist of psychedelic-focused biotechs following a White House executive order on psychedelic medicine, categorizing it as a psilocybin play with Phase 3 trials underway.